Advertisement
Screener

Connect Biopharma Holdings Limited (CNTB) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Connect Biopharma Holdings Limited Operating Cash Flow

Connect Biopharma Holdings Limited (CNTB) reported Operating Cash Flow of -$31.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12

  • Connect Biopharma Holdings Limited net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.92M.
  • Connect Biopharma Holdings Limited net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$16.00M.
  • Connect Biopharma Holdings Limited net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.25M.
  • Connect Biopharma Holdings Limited net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$17.41M.
  • Connect Biopharma Holdings Limited net cash provided by (used in) operating activities for fiscal 2025 was -$51.21M.
  • Connect Biopharma Holdings Limited net cash provided by (used in) operating activities for fiscal 2024 was -$23.61M.
  • Connect Biopharma Holdings Limited net cash provided by (used in) operating activities for fiscal 2023 was -$47.74M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$15.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$31.93M
10-Q · filed 2026-08-12
-$43.18M
derived: sum of 3 quarters · filed 2026-08-12
-$60.58M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$16.00M
10-Q · filed 2026-05-12
-$27.25M
derived: sum of 2 quarters · filed 2026-05-12
-$44.66M
derived: sum of 3 quarters · filed 2026-05-12
-$57.25M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$11.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$28.66M
derived: sum of 2 quarters · filed 2026-03-31
-$41.25M
derived: sum of 3 quarters · filed 2026-08-12
-$51.21M
10-K · filed 2026-03-31
2025-09-30-$17.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$30.00M
derived: sum of 2 quarters · filed 2026-08-12
-$39.96M
10-Q · filed 2025-11-12
-$42.27M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$12.59M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$22.55M
10-Q · filed 2026-08-12
-$24.87M
derived: sum of 3 quarters · filed 2026-08-12
-$37.88M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$9.96M
10-Q · filed 2026-05-12
-$12.28M
derived: sum of 2 quarters · filed 2026-05-12
-$25.29M
derived: sum of 3 quarters · filed 2026-05-12
-$32.98M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$2.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$15.33M
derived: sum of 2 quarters · filed 2026-03-31
-$23.02M
derived: sum of 3 quarters · filed 2026-03-31
-$23.61M
10-K · filed 2026-03-31
2024-09-30-$13.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$20.70M
derived: sum of 2 quarters · filed 2025-11-12
-$21.29M
10-Q · filed 2025-11-12
2024-06-30-$7.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
-$8.29M
10-Q · filed 2025-08-13
2024-03-31-$591.00K
10-Q · filed 2025-05-15
2023-12-31-$47.74M
10-K · filed 2025-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Yarrow Bioscience, Inc. (YARW)United States$0.070B
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
XBiotech Inc. (XBIT)United States$0.066B-1.56
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
HYPERION DEFI, INC. (HYPD)United States$0.065B
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57